Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human study of HMB-001 in Glanzmann thrombasthenia
ISRCTN66310879Phase 2Completed
- Sponsor
- Richmond Pharmacology
- Start
- Nov 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of sutacimig in Glanzmann thrombasthenia (GT) (2 arms), sponsored by Richmond Pharmacology. Primary endpoints: Safety and Preliminary prophylactic effect. Started Nov 2022; status: completed.
02
Drugs
sutacimig
03
Conditions
Glanzmann thrombasthenia (GT)
Beyond the preview
Go deeper on ISRCTN66310879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN66310879.